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Summary 
Objective: Anti-Müllerian hormone (AMH) is derived from the small antral follicles and an 
elevated level has been suggested to add value to the Rotterdam criteria for the diagnosis of 
PCOS in cases of diagnostic uncertainty. Therefore, the role of AMH in the classical 
phenotype of PCOS was defined within a Caucasian population.  
Design: This was a cross sectional study  
Patients: 65 women without PCOS and 110 women with PCOS fulfilling all 3 diagnostic 
Rotterdam criteria.  
Measurements: The main outcomes were the utility of serum AMH for the diagnosis of 
PCOS and its relationship to the metabolic parameters.  
Results. AMH was increased in PCOS compared to controls (p<0.001) Areas under the 
receiver operator curve showed AMH to be predictive of PCOS (0.76) using a cut off AMH 
of 46pmol/l, derived from the 95th percentile of the controls gave a 41% sensitivity and 86% 
specificity; an AMH cut off of 35pmol/l gave a 55% sensitivity and 79% specificity. Age and 
BMI adjusted multiple logistic regression showed that AMH was more predictive of PCOS 
independently of either serum testosterone (T) (OR = 4.04; 95% CI 1.42-11.11; p=0.007) or 
free androgen index (FAI) (OR = 3.90; 95% CI 1.40-10.83; p=0.009). 
Conclusion. Whilst an elevated AMH has poor sensitivity, it is four fold more likely to be 
associated with a diagnosis of PCOS, and supplementary to biochemical parameters will 
make a positive diagnosis of PCOS in 22% of patients when neither serum testosterone or 
FAI are elevated.           
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Introduction 
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders and 
affects 6-20 % of reproductive-aged women 1, 2. Currently PCOS is diagnosed using the 
Rotterdam, or Androgen Excess Society or NIH criteria, but it still remains a diagnosis to be 
made only after the exclusion of other conditions 3, 4. A diagnostic test that would positively 
identify a patient with PCOS and add value to the current diagnostic criteria would be of 
great benefit, and anti-Müllerian hormone (AMH) measurement has been suggested to add 
value to the Rotterdam criteria.  AMH is produced in the granulosa cells by the pre-antral and 
small antral follicles whose mechanism appears to be to inhibit the action of FSH on 
aromatase so assisting with the development of a single follicle for ovulation 5.  AMH is 
reported to be elevated in PCOS due to the increased small antral follicle count, where that 
increase in AMH may be a combination of the increased number of small antral follicles and 
the increased secretion of AMH per follicle 6. It has been suggested that AMH levels are a 
good marker for the size of the antral follicle pool. Ultrasound is used to measure the antral 
pool size but concerns over operator dependency are its main limitation and therefore a single 
serum measurement of AMH would be attractive 7. Several studies have been done on the 
utility of AMH in the diagnosis of PCOS 8, 9 with differing diagnostic thresholds being 
proposed, though a meta-analysis suggested a cut off of 35pmol/l with a sensitivity of 79.4% 
and a specificity of 82.8%8: however, it was noted that this may not be applicable to all 
PCOS subgroups and that the populations tended to be from fertility clinics rather than a 
general population and differing assays for AMH undertaken 8. A raised AMH is particularly 
associated with PCOS patients with all three diagnostic criteria 10; therefore the aim of this 
study was to look specifically at the utility of AMH for the diagnosis of PCOS within a well-
defined cohort of PCOS patients from the general population that fulfilled all 3 of the 
Rotterdam criteria to determine if it could be complementary to accepted androgen markers. 
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Materials and methods 
This was a cross sectional study involving 105 well characterised women with PCOS and 65 
women without PCOS who presented sequentially to the Department of Endocrinology and 
were recruited to the local PCOS biobank (ISRCTN70196169).  All patients gave written 
informed consent.  This study was approved by the Newcastle & North Tyneside Ethics 
committee.  The diagnosis of PCOS was based on all three diagnostic criteria of the 
Rotterdam consensus, namely clinical and/or biochemical evidence of hyperandrogenemia 
(Ferriman-Gallwey score >8; free androgen index >4 respectively), oligomenorrhea or 
amenorrhea and polycystic ovaries on transvaginal ultrasound 11, described as the type A 
phenotype in which AMH levels are highest.  Study participants had no concurrent illness, 
were not on any medication for the preceding 9 months except study medications and were 
not planning to conceive. Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, 
Cushing’s disease and androgen-secreting tumours were excluded by appropriate tests. All of 
the control women had regular periods, no clinical or biochemical hyperandrogenemia, no 
significant background medical history and none of them were on any medications including 
oral contraceptive pills or over the counter medications. All women underwent a 75g oral 
glucose tolerance test to exclude impaired glucose tolerance and type 2 diabetes. All women 
with PCOS and control women were Caucasian. Height, weight and waist circumference and 
body mass index (BMI) were performed according to WHO guidelines 12.  
 
 
Collection and analysis of blood samples 
Blood samples were collected immediately (within 5 min) and was stored frozen at -80OC 
pending analysis. Serum T was measured by LC/MS/MS on an Acquity UPLC system 
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coupled to a Quattro Premier XE mass spectrometer (Waters, Manchester, UK). Sex hormone 
binding globulin (SHBG) was measured by an immunometric assay with fluorescence 
detection on the DPC Immulite 2000 analyzer using the manufacturer’s recommended 
protocol. The free androgen index (FAI) was calculated as the total testosterone x 100/SHBG. 
Serum insulin was assayed using a competitive chemiluminescent immunoassay performed 
on the manufacturer’s DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, UK). The 
analytical sensitivity of the insulin assay was 2μU/ml, the coefficient of variation was 6%, 
and there was no stated cross-reactivity with proinsulin. Plasma glucose was measured using 
a Synchron LX 20 analyzer (Beckman-Coulter), using the manufacturer’s recommended 
protocol. The coefficient of variation for the assay was 1.2% at a mean glucose value of 5.3 
mmol/liter during the study period. The insulin resistance was calculated using the HOMA 
method [HOMA-IR=(insulin x glucose)/22.5]. Anti-Müllerian hormone was measured using 
a Beckman Coulter Access automated immunoassay.  Between run precision was <3% across 
the range measured. 
Statistical analysis 
Data trends were visually evaluated for AMH and each androgen and non-parametric tests 
were applied on data that violated the assumptions of normality when tested using 
Kolmogorov-Smirnov Test. Accordingly, comparative analysis evaluating androgen levels 
between PCOS cases and controls were performed using the non-parametric Mann-Whitney 
tests. Pearson’s correlations were also estimated to assess any linear relationship between 
AMH and the different parameters. Finally multivariable logistic regressions adjusting for 
age and BMI, serum testosterone or FAI were conducted to assess the effects of AMH in the 
diagnoses PCOS, firstly with a AMH categorical value of greater than 46 (based on the 95th 
percentile sensitivity of the ROC) and secondly based on AMH with a categorical value of 
greater than 35 according to the literature8. Significance was defined at α=0.05.  All analyses 
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were done using IBM-SPSS version 24.0. All values are given as (mean ± SD) unless 
specified. 
Results 
The baseline demographics of patients are given in Table 1.  Of the 170 subjects with a serum 
AMH, 4 of 65 controls and 3 of 105 PCOS subjects did not have a FAI level available. PCOS 
women were significantly younger (27.7 ± 6.3 years) than the controls (30.2 ± 6.30 years). 
Their body mass index (BMI), waist and hip circumferences were also significantly higher 
(p<0.0001) than the controls (Table 1). Patients with PCOS showed greater insulin, HOMA-
IR, 2 hour glucose post oral glucose tolerance test (OGTT) values (p<0.001) (Table 1). 
Serum T (1.5 ± 0.9 vs. 1.0 ± 0.5 nmol/L) and FAI (6.3 ± 5.7 vs. 2.5 ± 1.6) were significantly 
elevated in PCOS compared to control (p<0.001).  
All 105 PCOS women were categorized into a single phenotype according to the combination 
of all 3 major Rotterdam’s Consensus Criteria.   
The diagnostic upper threshold for AMH was calculated using the 95th percentile of the 
control for this population and was 46pmol/l (Figure 1).  Taking the categorical cut off of 
AMH greater than 46pmol/l, AMH was positive in 8 of 61 (13%) controls of whom 1 had 
both a raised FAI and serum T and 7 had neither. Of the 42/102 PCOS patients positive for an 
AMH with cut off of greater than 46pmol//l, 16/42 (38%) were positive for clinical 
hyperandrogendism (neither serum T nor FAI elevated) and 26/42 (62%) were positive if 
serum T and or FAI were elevated. Conversely, of the 60/102 with an AMH less than 
46pmol/l, 29/60 (48%) were positive for clinical hyperandrogendism (neither serum T nor 
FAI elevated) and 31/60 (52%) were positive if serum T and or FAI were elevated. 
Therefore, for those with neither a raised T nor FAI, AMH picked up an additional 16 of 102 
(16%) PCOS subjects. This gave a 41% sensitivity and 86% specificity for AMH at 46pmol/l. 
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It is suggested from the literature that an AMH greater than 35pmol/l is suggestive of a 
diagnosis of PCOS 8. Therefore, taking the categorical cut off of AMH greater than 35pmol/l, 
AMH was positive in 13 of 61 (21%) controls of whom 1 had both a raised FAI and serum T 
and 12 had neither. Of the 57/102 PCOS patients positive for an AMH with cut off of greater 
than 35pmol//l, 23/57 (40%) were positive for clinical hyperandrogendism (neither serum T 
nor FAI elevated) and 34/57 (60%) were positive if serum T and or FAI were elevated. 
Conversely, of the 45/102 with an AMH less than 35pmol/l, 22/45 (49%) were positive for 
clinical hyperandrogendism (neither serum T nor FAI elevated) and 23/45 (51%) were 
positive if serum T and or FAI were elevated. Therefore, for those with neither a raised T nor 
FAI, AMH picked up an additional 23 of 102 (22%) PCOS subjects. This gave a 55% 
sensitivity and 79% specificity for AMH at 35pmol/l. 
The PCOS groups with biochemical hyperandrogenemia showed a more metabolic profile 
with increased BMI, insulin and HOMA values (p<0.01) compared to those with clinical 
hyperandrogenism, but AMH levels did not differ between the 2 groups (Table 3). When the 
metabolic parameters were compared between those patients with an AMH of 35 or 46pmol/l 
with those less than 35pmol/l there were no differences in any of the metabolic parameters 
(Supplemental Table 1).  AMH as a quantitative measure, did not correlate to insulin, 
HOMA-IR or  CRP in either the control or PCOS subjects, but it did correlate to serum T and 
FAI in controls (r=0.3, p<0.05; r=0.35, P<0.01, respectively), but only to serum testosterone 
(r=0.2, p<0.05), and not FAI in the PCOS subjects.  
As individual tests, the age and BMI adjusted multiple logistic regression showed that for 
AMH at thresholds greater than either 35 or 46pmol/L, added significantly to both serum T 
and FAI in the prediction of PCOS, and when serum T and FAI were both included in the 
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model that AMH remained predictive of PCOS with an OR 3.8 and 4.5 (p<0.01) for a AMH 
cut off of 46 and 35pmol/l, respectively of (Table 2). 
Discussion 
It has been suggested that AMH may be a useful initial diagnostic test for PCOS with a cut 
off value of around 35pmol/l 8, 13. In accord with others, we found a raised AMH was strongly 
associated with a diagnosis of PCOS with a 4 fold odds ratio. Thus, in an analogous way to 
making a diagnosis of diabetes – where a diagnosis can be made using either a raised fasting 
plasma glucose, a raised 2 hour glucose value or a raised HbA1c 14 –then a raised serum 
testosterone, or a raised FAI or a raised AMH will identify an additional 22% more PCOS 
patients positively with a AMH threshold of 35 (16% with an AMH cut off of 46pmol/l). 
Therefore, there is additional discriminatory benefit for making the diagnosis of PCOS by 
measuring AMH in addition to the traditional androgen markers. The sensitivity of AMH for 
a diagnosis of PCOS was low with either cut off (46pmol/l; 41% and 35pmol/l;55%) and 
lower than that reported of 79%, though with a similar specificity and likely reflected the 
general population of study rather than from fertility clinics8 
 
The number of patients with clinical hyperandrogenism who had a raised AMH but had no 
biochemical evidence of hyperandrogenaemia (as evidenced by normal serum T and FAI) 
was 16/42 (38%) v 23/57 (40%) using 46pmol/L and 35pmol/L thresholds respectively. If 
one then applies the AMH levels at either cut off to that of the NIH or Androgen excess 
society guidelines for the diagnosis of PCOS 4, 15 AMH measurement would have added 
additional value in making a positive diagnosis of PCOS. Those PCOS patients with 
biochemical hyperandrogenemia had a more metabolic profile with a higher BMI than those 
with clinical hyperandrogenism, but AMH levels were no different between the 2 groups 
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showing that AMH was independent of the metabolic parameters. This was confirmed when 
no difference between PCOS groups were seen for those metabolic factors when those with 
elevated AMH (greater than 35 and 46pmol/l) were compared to those with levels below 
35pmol/l.  
 
Positive aspects of this study included the significant number of subjects in the study of a 
homogeneous Caucasian population, the type A phenotype for PCOS all with the same 3 
diagnostic criteria fulfilled where AMH noted to be the highest in this population 10, 16. All 
patients had polycystic ovaries on ultrasound and therefore it might have expected all of the 
AMH values to be elevated. Why this was not the case is likely due to the observation that 
AMH values have been shown to be lower in anovulation and many of these patients may 
have been anovulatory, though this was not determined in this study.  AMH levels have been 
correlated with serum testosterone, but not to BMI or to insulin resistance i.e. AMH is likely 
to be a marker of the consequence of PCOS rather than the instigator 17. Limitations of this 
study were in part the converse of the strengths. This was a narrow group of individuals all 
with the same 3 diagnostic criteria fulfilled for the diagnosis of PCOS, and other PCOS 
phenotypes not included. In addition, this was a narrow ethnic group and therefore more 
detailed studies including the other PCOS phenotypes with other ethnicities are required. 
In conclusion, whilst an elevated AMH has poor sensitivity, it is four fold more likely to be 
associated with a diagnosis of PCOS which, in this study, results in its measurement 
identifying an additional 16% or 22% of patients (using AMH cut offs of 35 or 46pmol/l, 
respectively) as having PCOS when routine measurement of androgen concentrations are not 
elevated. This means there may be merit in considering AMH as a marker which 
complements androgen measurement in the biochemical assessment of PCOS. 
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            Legend to Table 1.  
Demographics of the 170 subjects involved in the study, 65 women without PCOS and 105 
women with PCOS. The diagnosis of PCOS was based on all three diagnostic criteria of the 
Rotterdam consensus, namely clinical and biochemical evidence of hyperandrogenemia 
(Ferriman-Gallwey score >8; free androgen index >4 respectively), oligomenorrhea or 
amenorrhea and polycystic ovaries on transvaginal ultrasound. These women therefore 
represented the phenotype with the greatest metabolic features. 
            
Legend to Table 2 
Logistic regression analysis for the diagnosis of PCOS for either serum testosterone or Free 
Androgen Index (FAI).  
A, anti-Müllerian hormone as categorical data with a value of greater than 46pmol/L (95th 
percentile on ROC).  
B, anti-Müllerian hormone as categorical data with a value of greater than 35pmol/L 
according to the literature 8. There was a four fold prediction of PCOS by AMH and both cut 
off values appeared equally predictive.  
 
Legend to Table 3. The PCOS groups with biochemical hyperandrogenemia showed a more 
metabolic profile with increased BMI, insulin and HOMA-IR values compared to those 
PCOS women with clinical hyperandrogenism, but AMH levels did not differ between the 2 
groups. (BMI=body mass index; FAI= free androgen index; T = serum testosterone; HOMA-
IR =Homeostasis model of assessment – insulin resistance). 
 
Legend to supplemental Table 1. A. Comparison of the metabolic parameters between those 
PCOS women with a AMH greater than 46pmol/l compared to those with a AMH less than 
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35pmol/l. B, A. Comparison of the metabolic parameters between those PCOS women with a 
AMH greater than 35pmol/l compared to those with a AMH less than 35pmol/l.  In either 
case it can be seen that there is no difference between the groups showing that AMH is 
independent of the metabolic parameters. 
  
 Legend to Figure 1 
Receiver operator curves for anti-Müllerian hormone showing that AMH is predictive of the 
diagnosis of PCOS with an area under the curve of 0.76+/-0.04SE. 
